A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)

Inclusion Criteria: * History of allergic rhinitis/rhinoconjunctivitis to house dust of 1 year duration or more (with or without asthma) * If female of childbearing potential, has a negative urine pregnancy test at screening and agrees to remain abstinent or use (or have their partner use) 2 acceptable methods of birth control within the projected duration of the study. Exclusion Criteria: * Sensitized and regularly exposed to animal dander and molds, (e.g. present in the home, job, etc.) * Sensitized and regularly exposed to seasonal allergens (i.e., birch or grass pollen) * Immunosuppressive treatment within 3 months prior to screening (except steroids for allergic and asthma symptoms) * History of chronic urticaria and/or angioedema within 2 years prior to screening * Previous immunotherapy treatment with any HDM allergen for more than 1 month within 3 years prior to screening * Ongoing treatment with any specific immunotherapy * History of anaphylaxis with cardiorespiratory symptoms with prior immunotherapy, due to an unknown cause or to an inhalant allergen * Unstable uncontrolled/partially controlled or severe asthma, or life-threatening asthma attack or an occurrence of any clinical deterioration of asthma that resulted in emergency treatment, hospitalization due to asthma, or treatment with systemic corticosteroids (but allowing short-acting beta agonists \[SABA\]) within 3 months prior to screening * Asthma requiring medium- or high-dose inhaled corticosteroid (IC…